Roche Holding AG Q2 2026 Earnings Recap

Roche’s shares gained 6.8% post-earnings, reflecting upbeat core operating profit growth and margin expansion that outpaced sales growth, supported by strong pipeline progress and regulatory milestones.

Key Takeaways

• Core operating profit rose 10%, outstripping sales growth of 6%, resulting in a 1.7 percentage point increase in the core operating margin.
• Core EPS increased by 9%, with strong contributions from both pharma (6% growth) and diagnostics (3% growth, or 7% excluding China impact and flu season effects).
• Regulatory advancements included five U.S. FDA priority reviews for Tecentriq and Gazyva, alongside positive Phase III trial results supporting an 80% success rate this year.
• The company highlighted disciplined business development deals and a rich late-stage pipeline with multiple upcoming Phase III readouts and new molecular entity launches through 2029.
• Diagnostic segment progress included recent acquisitions and product launches that are expected to contribute to sustained growth despite healthcare pricing reforms and seasonal headwinds.